A Phase 1, Open-label, Randomized, Crossover, Oral, Single Dose Study To Estimate The Relative Bioavailability Of Pf-06291826 (Tafamidis) Following Administration Of A Tafamidis Free Acid Tablet Formulation In Healthy Subjects Under Fasted And Fed Conditions
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
- 03 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Jul 2015.
- 23 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.